US stocks movement: VeraDermics plummeted on November 12 as major shareholders reduced holdings, losses widened, and no products were approved
Bitget异动解读2026/11/12 14:41VeraDermics November 12 Plunge Interpretation
Keywords: major shareholder reduction, widening losses, no approved products
1. On November 12, a shareholder holding 10% of the shares proposed to sell their VeraDermics holdings, increasing stock supply pressure.
2. On November 10, the company disclosed its Q3 2026 financial report. The net loss for the first three quarters was $71.733 million, significantly wider than $48.148 million in the same period last year. The company currently has no approved commercial products, and its business depends on the future clinical and regulatory progress of VDPHL01.
(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Crypto prices
More
